Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
March 2021
-
Challenging a young scientist to focus on patients
Novartis researcher Joana Silva had a life-changing experience with a mentor.
-
Teaching a daughter the power of purpose
Racey Muchilwa, Head of Sub-Saharan Africa for Novartis, reflects on her mother’s calling as a teacher.
-
Inspiring a daughter to make her own path
Chief Talent and People Solutions Officer Tripti Jha’s mother prioritized her learning in a rural region of India with limited opportunities for girls.
-
Key ReleaseNovartis announces change to the Executive CommitteeShannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021Thomas Kendris appointed Chief Legal Officer ad interimBasel, March 5, 2021 — Novartis announced today that Shannon Thyme…
-
Media ReleaseNovartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidateNovartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.Novartis plans to manufacture the mRNA and bulk drug product…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General MeetingShareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelleLes actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General MeetingShareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg…
-
Media ReleaseDie Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gutDie Aktionäre bewilligen die 24. Dividendenerhöhung in Folge. Für 2020 wird die Dividende auf CHF 3.00 (+1,7%) je Aktie erhöht, was einer Rendite von 3,8%1 und einem Anteil des freien…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelleLes actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-…
-
Take a visual tour of medicines that target RNA
A new type of medicine that targets RNA was discovered by accident and could change the way some diseases are treated.
-
Featured NewsOn a mission to transform planetary health
The first One Young World – Novartis Caucus took place virtually on February 11, 2021.
Pagination
- ‹ Previous page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- …
- 150
- › Next page